Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
H. J. Deeg
No relevant relationships to disclose
O. Odenike
No relevant relationships to disclose
B. L. Scott
No relevant relationships to disclose
Z. Estrov
No relevant relationships to disclose
J. E. Cortes
No relevant relationships to disclose
D. A. Thomas
No relevant relationships to disclose
H. J. Zhu
Employment or Leadership Position - S*Bio
Stock Ownership - S*Bio
* H. Kantarjian
No relevant relationships to disclose
S. Verstovsek
No relevant relationships to disclose